Glycosidic Prodrugs of Highly Potent Bifunctional Duocarmycin Derivatives for Selective Treatment of Cancer

Abstract

Cytotoxicities almost a million times lower than the prevailing active compounds, which can have IC50 values of about 100 fM, are displayed by new glycosidic prodrugs for selective tumor therapy (see example; gray C, white H, green Cl, blue N, red O). The cytotoxicity of these new active compounds is presumably not attributable to DNA intra- or DNA inter-strand cross-linking, but might be based on an as yet unknown mechanism. Detailed facts of importance to specialist readers are published as ”Supporting Information”. Such documents are peer-reviewed, but not copy-edited or typeset. They are made available as submitted by the authors. Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.